BRCA1 and pancreatic neoplasm: Poly (ADP-ribose) polymerase inhibitors are the current standard of care for various solid tumors harboring P/LP germline BRCA1/2 variants, such as ovarian cancer18 and metastatic breast,19 prostate20,21 and pancreatic cancers,22 and may also benefit individuals with germline variants in HRD genes beyond BRCA1/2.